Bibliography
- Doggrell SA. Clinical benefits of ezetimibe; absence of proof is just that. Expert Opin Pharmacother 2013; In press
- Doggrell SA. The ezetimibe controversy - can this be resolved by comparing the clinical trials with simvastatin and ezetimibe alone and together? Expert Opin Pharmacother 2012;13:1469-80
- Patel AY, Pillarisetti J, Marr J, Vacek JL. Ezetimibe in combination with a statin does not reduce all-cause mortality. J Clin Med Res 2013;5:275-80
- Lin CF, Gau CS, Wu FL, et al. Impact of ezetimibe coadministered with statins on cardiovascular events following acute coronary syndrome: a 3-year population-based retrospective cohort study in Taiwan. Clin Ther 2011;33:1120-31
- Hayek S, CanepaEscaro F, Sattar A, et al. Effect of ezetimibe on major atherosclerotic disease events and all-cause mortality. Am J Cardiol 2013;111:532-9
- Gouni-Berthold I, Mikhailidis DP, Rizzo M. Clinical benefits of ezetimibe use: is absence of proof, proof of absence? Expert Opin Pharmacother 2012;13:1985-8
- Paraskevas KI, Veith FJ, Mikhailidis DP. Carotid intima-media thickness and ezetimibe: the end of a misunderstanding? Curr Vasc Pharmacol 2011;9:381-4
- Fleg JL, Mere M, Howard BV, et al. Effects of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetic Study) trial. J Am Coll Cardiol 2008;52:2198-205
- Meaney A, Ceballos G, Asbun J, et al. The VYtorin on carotid intima-media thickness and overall arterial rigidity (VYCTOR) study. J Clin Pharmacol 2009;49:838-47
- Nordestgaard BG, Chapman MJ, Humphries SE, et al. for the European Atherosclerosis Society Consensus. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus Statement of the European Atherosclerosis Society. Eur Heart J 2013; Epub ahead of print